Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2.48
CYTR's Cash to Debt is ranked lower than
69% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 83.29 vs. CYTR: 2.48 )
Ranked among companies with meaningful Cash to Debt only.
CYTR' s Cash to Debt Range Over the Past 10 Years
Min: 2.37  Med: No Debt Max: No Debt
Current: 2.48
Equity to Asset 0.39
CYTR's Equity to Asset is ranked lower than
77% of the 711 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CYTR: 0.39 )
Ranked among companies with meaningful Equity to Asset only.
CYTR' s Equity to Asset Range Over the Past 10 Years
Min: 0.16  Med: 0.79 Max: 0.95
Current: 0.39
0.16
0.95
F-Score: 2
Z-Score: -10.68
M-Score: -4.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -32507.00
CYTR's Operating margin (%) is ranked lower than
97% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. CYTR: -32507.00 )
Ranked among companies with meaningful Operating margin (%) only.
CYTR' s Operating margin (%) Range Over the Past 10 Years
Min: -63278  Med: -9129.8 Max: -80.47
Current: -32507
-63278
-80.47
Net-margin (%) -32700.00
CYTR's Net-margin (%) is ranked lower than
97% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. CYTR: -32700.00 )
Ranked among companies with meaningful Net-margin (%) only.
CYTR' s Net-margin (%) Range Over the Past 10 Years
Min: -58587  Med: -3290.42 Max: 408
Current: -32700
-58587
408
ROE (%) -173.82
CYTR's ROE (%) is ranked lower than
90% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. CYTR: -173.82 )
Ranked among companies with meaningful ROE (%) only.
CYTR' s ROE (%) Range Over the Past 10 Years
Min: -271.11  Med: -86.58 Max: 1.39
Current: -173.82
-271.11
1.39
ROA (%) -95.24
CYTR's ROA (%) is ranked lower than
85% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. CYTR: -95.24 )
Ranked among companies with meaningful ROA (%) only.
CYTR' s ROA (%) Range Over the Past 10 Years
Min: -116.2  Med: -46.69 Max: 1.13
Current: -95.24
-116.2
1.13
ROC (Joel Greenblatt) (%) -4126.42
CYTR's ROC (Joel Greenblatt) (%) is ranked lower than
79% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. CYTR: -4126.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CYTR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -12894.39  Med: -3246.77 Max: -723.27
Current: -4126.42
-12894.39
-723.27
Revenue Growth (3Y)(%) -20.60
CYTR's Revenue Growth (3Y)(%) is ranked lower than
75% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. CYTR: -20.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CYTR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -81.8  Med: -20.6 Max: 175.3
Current: -20.6
-81.8
175.3
EBITDA Growth (3Y)(%) 4.50
CYTR's EBITDA Growth (3Y)(%) is ranked higher than
56% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. CYTR: 4.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CYTR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -67.2  Med: -10.3 Max: 143.5
Current: 4.5
-67.2
143.5
EPS Growth (3Y)(%) 7.50
CYTR's EPS Growth (3Y)(%) is ranked higher than
65% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CYTR: 7.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CYTR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -55.4  Med: -11.7 Max: 94.8
Current: 7.5
-55.4
94.8
» CYTR's 10-Y Financials

Financials (Next Earnings Date: 2017-03-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

CYTR Guru Trades in

CYTR Guru Trades in

Q2 2014

CYTR Guru Trades in Q2 2014

George Soros Sold Out
Paul Tudor Jones Sold Out
» More
Q3 2016

CYTR Guru Trades in Q3 2016

Jim Simons 690,380 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with CYTR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:DYAI, AMEX:ATNM, NAS:KMPH, NAS:AEGR, OTCPK:TBQBF, NAS:AVIR, NAS:PBMD, OTCPK:PRTX, OTCPK:MTFBF, OTCPK:KBIO, NAS:ADHD, NAS:HTBX, OTCPK:COTQF, NAS:EBIO, AMEX:PLX, NAS:OCRX, NAS:CNAT, NAS:MTP, NAS:INFI, NAS:VCEL » details
Traded in other countries:CX5N.Germany,
CytRx Corp is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes three clinical-stage drug candidates in various stages of development: Aldoxorubicin, Tamibarotene, and Bafetinib.

CytRx Corp is a Delaware corporation, incorporated in 1985. The Company is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes three clinical-stage drug candidates in various stages of development: Aldoxorubicin, Tamibarotene, and Bafetinib. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors. Tamibarotene is an orally available, synthetic retinoid, rationally designed to overcome resistance and reduce the toxic side effects of differentiation therapy with all-trans retinoic acid, a component of the current first-line treatment for acute promyelocytic leukemia, or APL. Bafetinib (formerly INNO-406) is an orally bioavailable, rationally-designed inhibitor of several Src kinases developed by the Japanese pharmaceutical company, Nippon Shinyaku, to overcome some of the limitations of Gleevec and other tyrosine kinase inhibitors in resistant chronic myelogenous leukemia. The Company do not have manufacture supplies of aldoxorubicin or any of our other product candidates accordingly it is dependent upon third-party manufactures, or potential future strategic alliance partners, to manufacture these supplies. The Company has manufacturing supply arrangements in place with respect to a portion of the clinical supplies needed for the clinical development programs for aldoxorubicin. The Company's plan is to establish its own sales force and marketing capability in order to commercialize aldoxorubicin in the U.S. and to seek a marketing partner for commercialization in other territories. It is subjected to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials.

Ratios

vs
industry
vs
history
P/B 2.14
CYTR's P/B is ranked higher than
68% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: 3.57 vs. CYTR: 2.14 )
Ranked among companies with meaningful P/B only.
CYTR' s P/B Range Over the Past 10 Years
Min: 1.39  Med: 3.75 Max: 67.04
Current: 2.14
1.39
67.04
P/S 173.33
CYTR's P/S is ranked lower than
87% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 12.03 vs. CYTR: 173.33 )
Ranked among companies with meaningful P/S only.
CYTR' s P/S Range Over the Past 10 Years
Min: 3.49  Med: 215.54 Max: 2565
Current: 173.33
3.49
2565
Current Ratio 3.06
CYTR's Current Ratio is ranked lower than
63% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CYTR: 3.06 )
Ranked among companies with meaningful Current Ratio only.
CYTR' s Current Ratio Range Over the Past 10 Years
Min: 1.04  Med: 4.21 Max: 27.1
Current: 3.06
1.04
27.1
Quick Ratio 3.06
CYTR's Quick Ratio is ranked lower than
60% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. CYTR: 3.06 )
Ranked among companies with meaningful Quick Ratio only.
CYTR' s Quick Ratio Range Over the Past 10 Years
Min: 1.04  Med: 4.19 Max: 27.1
Current: 3.06
1.04
27.1
Days Sales Outstanding 197.10
CYTR's Days Sales Outstanding is ranked lower than
89% of the 595 Companies
in the Global Biotechnology industry.

( Industry Median: 63.02 vs. CYTR: 197.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYTR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.94  Med: 235.06 Max: 16870.3
Current: 197.1
4.94
16870.3

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -29.50
CYTR's 3-Year Average Share Buyback Ratio is ranked lower than
78% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. CYTR: -29.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CYTR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -53.9  Med: -27.6 Max: -1.5
Current: -29.5
-53.9
-1.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.74
CYTR's Price/Net Cash is ranked higher than
78% of the 875 Companies
in the Global Biotechnology industry.

( Industry Median: 6.19 vs. CYTR: 2.74 )
Ranked among companies with meaningful Price/Net Cash only.
CYTR' s Price/Net Cash Range Over the Past 10 Years
Min: 0.55  Med: 5.15 Max: 458
Current: 2.74
0.55
458
Price/Net Current Asset Value 2.36
CYTR's Price/Net Current Asset Value is ranked higher than
79% of the 1006 Companies
in the Global Biotechnology industry.

( Industry Median: 5.65 vs. CYTR: 2.36 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CYTR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.43  Med: 4.31 Max: 108.89
Current: 2.36
0.43
108.89
Price/Tangible Book 2.15
CYTR's Price/Tangible Book is ranked higher than
75% of the 1150 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. CYTR: 2.15 )
Ranked among companies with meaningful Price/Tangible Book only.
CYTR' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.34  Med: 3.6 Max: 63.61
Current: 2.15
0.34
63.61
Price/Median PS Value 0.80
CYTR's Price/Median PS Value is ranked higher than
58% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CYTR: 0.80 )
Ranked among companies with meaningful Price/Median PS Value only.
CYTR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 0.31 Max: 8.65
Current: 0.8
0.01
8.65
Earnings Yield (Greenblatt) (%) -434.80
CYTR's Earnings Yield (Greenblatt) (%) is ranked lower than
99% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. CYTR: -434.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CYTR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -434.8  Med: 1854.1 Max: 12962.6
Current: -434.8
-434.8
12962.6

More Statistics

Revenue (TTM) (Mil) $0.20
EPS (TTM) $ -0.94
Beta2.06
Short Percentage of Float14.91%
52-Week Range $0.41 - 3.66
Shares Outstanding (Mil)96.94

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 17 41
EPS ($) -0.92 -0.46 -0.05
EPS w/o NRI ($) -0.92 -0.46 -0.05
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for CYTR

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: CYTR, API, CLGX, PLBC, ARTC Mar 05 2012 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CFO Buys Highlight: CYTR, PZZI, AGYS, PLBC Feb 27 2012 
CytRx Corp. Reports Operating Results (10-K) Mar 11 2011 
CytRx Corp. Reports Operating Results (10-Q) Nov 08 2010 
CytRx Corp. Reports Operating Results (10-Q) Aug 09 2010 
CytRx Corp. Reports Operating Results (10-Q) May 06 2010 
CytRx Corp. Reports Operating Results (10-Q) Nov 09 2009 
CytRx Corp. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
Leading Sarcoma Expert Dr. Earl W. Brien Joins CytRx Board of Directors Dec 02 2016
CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA Nov 29 2016
CytRx Corp Conference Call to Discuss Results of Phase 3 Trial of Aldoxorubicin scheduled for 8:30... Nov 29 2016
CytRx Reports Statistically Significant Updated Results from Pivotal Phase 3 Trial of Aldoxorubicin... Nov 29 2016
CYTRX CORP Files SEC form 8-K, Regulation FD Disclosure Nov 29 2016
CYTRX CORP Financials Nov 17 2016
CytRx Gets a Second Look (CYTR) Nov 16 2016
Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive Nov 15 2016
CYTRX CORP Files SEC form 8-K, Unregistered Sale of Equity Securities Nov 14 2016
CytRx Presents Positive Interim Results from On-going Phase 1b/2 Aldoxorubicin Combination Clinical... Nov 11 2016
CytRx Presents Positive Interim Results from On-going Phase 1b/2 Aldoxorubicin Combination Clinical... Nov 11 2016
CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition Nov 09 2016
CytRx Reports Third Quarter 2016 Financial Results Nov 09 2016
CytRx reports 3Q loss Nov 09 2016
CytRx reports 3Q loss Nov 09 2016
CytRx Reports Third Quarter 2016 Financial Results Nov 09 2016
CYTRX CORP Files SEC form 10-Q, Quarterly Report Nov 09 2016
CYTRX CORP Files SEC form 8-K, Change in Directors or Principal Officers Oct 19 2016
What CytRx Latest Trial Results Really Mean (CYTR) Oct 17 2016
CytRx Presents Interim Results from On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination... Oct 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)